Company intelligence / Profile preview

GlycoT Therapeutics

Ellicott City, Maryland, United States

Ownership: Private
Development stage: Other

Overview

GlycoT Therapeutics is a preclinical/platform-focused company providing chemoenzymatic glycoengineering technology for therapeutic antibodies and other glycoproteins; there are no disclosed clinical-stage therapeutic programs, but the platform is used to generate homogeneous glycoforms and site-specific antibody-drug conjugates and has been sublicensed to pharma partners such as Daiichi Sankyo and Genovis for research and diagnostic applications.[2][5]

Modalities: AntibodyAntibody-drug conjugateProteinRecombinant protein
Industry: Drug Discovery Services

Partnerships

Daiichi Sankyo (sublicense of glycoengineering technology)[2][6]Genovis (cross-licensing agreements on antibody conjugation technology)[2]

Beyond the preview

Go deeper on GlycoT Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoT Therapeutics.

Explore the full profile